Upon oral administration of small-molecule BACE1 inhibitors like lanabecestat, atabecestat in AD patients displayed reduced Aβ, total tau, and phosphorylated tau levels in the CSF, but the usage of these drugs is terminated due to side effects of skin rashes, liver toxicity, and neuropsychiatric symptoms [183],[184]. Here, MAPT is linked to Alzheimer disease.